TLR‐7/8a adjuvant systems have been shown to enhance CD8 T‐cell responses in cancer vaccination models,39 induce an influx of migratory DCs to the LN, and increase DC antigen uptake during vaccine responses,40 as well as increase antibody responses to HIV vaccines in non‐human primates.41 This evidence concerns the gene CD8A and cancer.